Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Current Oncology (Toronto, Ont.)|March 12, 2019
Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancerS A Laurie, S Banerji, N Blais, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung TumorsJ von Pawel, R von Roemeling, U Gatzemeier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2015
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)S Ramalingam, G Goss, R Rosell, et al.
Current Oncology (Toronto, Ont.)|June 23, 2016
Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancerB Melosky, J Agulnik, R Albadine, et al.
Current Oncology (Toronto, Ont.)|November 23, 2018
Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancerB Melosky, P Cheema, J Agulnik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trialL Paz-Ares, E-H Tan, K O'Byrne, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2013
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29S A Laurie, B J Solomon, L Seymour, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2016
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trialsJ C-H Yang, L V Sequist, C Zhou, et al.
Pageof 4